世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

創薬サービス市場:プロセス毎(目標選択、検証、リード最適化)、タイプ毎(医薬品化学、DMPK)、薬品タイプ毎(小分子、生物製剤)、治療毎(腫瘍、神経)、企業毎(ティア1、2、3) - 2025年までの世界市場予測

Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2020年1月US$4,950
シングルユーザライセンス
170 150

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)の創薬サービス市場に関する調査レポートです。

“Drug discovery services market to register a CAGR of 12.1% from 2020 to 2025.”

The global drug discovery services market is projected to reach USD 19.1 billion by 2025 from USD 10.7 billion in 2020, at a CAGR of 12.1%  from 2020 to 2025. The growth of the industry is driven primarily by factors such as growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing and clinical trial services, initiatives for research on rare diseases and orphan drugs, and focus on drug discovery. Growth in the biologics market and patent expiries will further provide opportunities in the drug discovery services industry. Developing economies are expected to offer a wide range of growth opportunities for players in the market.

“The Hit-to-Lead process segment is anticipated to grow at the fastest growth rate during the forecast period.”

Based on the process, the drug discovery services market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. Hit-to-lead identification process is anticipated to be the fastest-growing segment due to the high outsourcing of these services to CROs by the pharmaceutical companies and the emerging advanced technologies for high-throughput screening (HTS) and H2L as well as reductions in development time.

“Medicinal Chemistry segment is estimated to account for the largest share of the drug discovery services market in 2020.”

Based on type, the drug discovery services market is segmented into medicinal chemistry services, biology services, and drug metabolism and pharmacokinetics (DMPK). The medicinal chemistry services segment is estimated to account for the largest share of the drug discovery services market due to the widespread application of medicinal chemistry in various phases of preclinical drug discovery to deliver robust candidates.

“Oncology segment is anticipated to grow at the fastest growth rate during the forecast period.”

Based on the therapeutic area, the drug discovery services market is segmented into oncology, cardiovascular diseases, neurology, infectious and immune system diseases, digestive system diseases, and other therapeutic areas. Of all these therapeutic segments,  oncology will grow at the fastest CAGR in the drug discovery services market in 2019. The high growth of the oncology segment can be attributed to factors such as the increasing number of patients who have cancer, the subsequent increase in the demand for cancer therapies and the growing R&D expenditure by pharmaceutical companies in this therapeutic area.

“North America  is expected to dominate the drug discovery services market in 2020.”

North America, which includes the US and Canada, is estimated to account for the largest share of the drug discovery services market. The large share of this region can primarily be attributed to the presence of well-established CROs; rising R&D expenditure by pharmaceutical & biopharmaceutical companies and the availability of latest techniques, instruments, and facilities for drug discovery research are driving the growth of this region.

Breakdown of supply-side primary interviews, by company type, designation, and region:

- By Company Type: Tier 1 (40%) , Tier 2 (30%), and Tier 3 (30%)
- By Designation: C-level (27%), Director-level (18%), and Others (55%)
- By Region: North America (50%), Europe (20%), Asia Pacific (20%), and RoW (10%)

The key players operating in this market include Thermo Fisher Scientific, Inc. (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Eurofins Scientific (Luxembourg), WuXi AppTec (China), GenScript Biotech Corporation (China), Jubilant Life Sciences (India), Laboratory Corporation of America Holdings (US), Piramal Enterprises Ltd. (India), Viva Biotech (China), Domainex (UK), Shanghai Medicilon, Inc. (China), TCG Lifesciences Pvt. Limited (India), Frontage Holdings (US), Pharmaceutical Product Development, LLC (US), Syngene International Ltd. (India), ChemPartner Co., Ltd (China), Aurigene Discovery Technologies Limited (A subsidiary of Dr. Reddy’s, Laboratories) (India), and Selvita S.A. (Poland). Services launches, expansions,  collaborations, agreements, partnerships and acquisitions are the key growth strategies followed by most players in this market.

Research Coverage

This report studies the drug discovery services market based on the process, type, drug type, therapeutic area, company type, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and trends) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro-markets concerning their growth trends, prospects, and contributions to the total drug discovery services market. The report forecasts the revenue of the market segments concerning four major regions.
 
Reasons to Buy the Report:

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the drug discovery services offered by the key 20 players in the drug discovery services market. The report analyzes the drug discovery services market by process, type, drug type, therapeutic area, company type, and region.

- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various drug discovery services, their adoption, type of applications across key geographic regions.

- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the drug discovery services market

- Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the drug discovery services market along with a competitive leadership mapping of up to 25 players in the market.



目次

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 22
2 RESEARCH METHODOLOGY 23
2.1 RESEARCH DATA 23
2.1.1 SECONDARY DATA 24
2.1.1.1 Key data from secondary sources 25
2.1.2 PRIMARY DATA 25
2.2 MARKET SIZE ESTIMATION 26
2.2.1 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 26
2.2.2 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 27
2.2.3 GROWTH FORECAST 27
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 28
2.4 ASSUMPTIONS FOR THE STUDY 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 34
4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW 34
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE & COUNTRY (2020) 35
4.3 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 38
5.2.1 DRIVERS 38
5.2.1.1 Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry 38
5.2.1.2 Increasing demand for outsourcing analytical testing and clinical
trial services 39
5.2.1.3 Initiatives for research on rare diseases and orphan drugs 40
5.2.1.4 Focus on drug discovery 42
5.2.2 RESTRAINTS 43
5.2.2.1 High cost of drug discovery and development 43
5.2.2.2 Stringent regulations governing drug discovery and animal usage 44
5.2.3 OPPORTUNITIES 45
5.2.3.1 Growth in the biologics market 45
5.2.3.2 Patent expiries 45
5.2.3.3 Emerging markets 45
5.2.4 TRENDS 46
5.2.4.1 Growing adoption of artificial intelligence-based tools for
drug discovery 46
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS 48
6.1 INTRODUCTION 49
6.2 TARGET SELECTION 49
6.2.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT
THE GROWTH OF THIS MARKET 49
6.3 TARGET VALIDATION 50
6.3.1 RISING NUMBER OF DRUG DISCOVERY RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH 50
6.4 HIT-TO-LEAD IDENTIFICATION 51
6.4.1 HIT-TO-LEAD IDENTIFICATION IS THE LARGEST PROCESS SEGMENT IN
THE MARKET 51
6.5 LEAD OPTIMIZATION 52
6.5.1 LEAD OPTIMIZATION REQUIRES STATE-OF-THE-ART INFORMATICS SYSTEMS TO FACILITATE TRANSPARENT PRESENTATION AND ANALYSIS 52
6.6 CANDIDATE VALIDATION 53
6.6.1 CANDIDATE VALIDATION SEGMENT TO GROW AT A HIGH CAGR DURING
THE FORECAST PERIOD 53
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE 54
7.1 INTRODUCTION 55
7.2 MEDICINAL CHEMISTRY SERVICES 55
7.2.1 WIDE APPLICATIONS OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY ARE A MAJOR FACTOR DRIVING MARKET GROWTH 55
7.3 BIOLOGY SERVICES 56
7.3.1 RESTRICTIONS ON THE USAGE OF ANIMALS IN RESEARCH ACTIVITIES MAY LIMIT MARKET GROWTH 56
7.4 DRUG METABOLISM & PHARMACOKINETICS 57
7.4.1 DMPK STUDIES ARE EMPLOYED AT THE DISCOVERY, CANDIDATE SELECTION, INVESTIGATIONAL NEW DRUG, AND NEW DRUG APPLICATION STAGES 57

8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE 58
8.1 INTRODUCTION 59
8.2 SMALL-MOLECULE DRUGS 59
8.2.1 INCREASING NUMBER OF START-UPS AND NEW ENTRANTS IN THE SMALL-MOLECULE DRUGS SEGMENT WILL DRIVE THE GROWTH OF THIS MARKET DURING THE FORECAST PERIOD 59
8.3 BIOLOGIC DRUGS 60
8.3.1 HIGH SET-UP COSTS OF THE INSTRUMENTS REQUIRED FOR BIOLOGIC DRUG MANUFACTURING MAY LIMIT MARKET GROWTH TO A CERTAIN EXTENT 60
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA 62
9.1 INTRODUCTION 63
9.2 ONCOLOGY 64
9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH 64
9.3 NEUROLOGY 66
9.3.1 INCREASING NUMBER OF PATIENTS SUFFERING FROM NEUROLOGICAL DISORDERS IS DRIVING MARKET GROWTH 66
9.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES 67
9.4.1 EMERGENCE OF NEW INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 67
9.5 DIGESTIVE SYSTEM DISEASES 68
9.5.1 AS THERE IS A HUGE POPULATION SEEKING EFFECTIVE REMEDIES FOR DIGESTIVE DISEASES, PHARMACEUTICAL COMPANIES ARE INVESTING SIGNIFICANTLY IN R&D FOR THE DEVELOPMENT OF INNOVATIVE DRUGS 68
9.6 CARDIOVASCULAR DISEASES 69
9.6.1 HIGH GLOBAL BURDEN OF CARDIOVASCULAR DISEASES HAS INCREASED THE FOCUS ON DEVELOPING EFFECTIVE DRUGS 69
9.7 OTHER THERAPEUTIC AREAS 70
10 DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE 71
10.1 INTRODUCTION 72
10.2 TIER 1 PHARMACEUTICAL COMPANIES 72
10.3 TIER 2 PHARMACEUTICAL COMPANIES 73
10.4 TIER 3 PHARMACEUTICAL COMPANIES 73
11 DRUG DISCOVERY SERVICES MARKET, BY REGION 74
11.1 INTRODUCTION 75
11.2 NORTH AMERICA 75
11.2.1 US 79
11.2.1.1 Availability of advanced R&D infrastructure has driven the growth of the US market 79
11.2.2 CANADA 82
11.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth 82

11.3 EUROPE 85
11.3.1 GERMANY 88
11.3.1.1 Government support and flexible labor laws are driving the growth of the German drug discovery services market 88
11.3.2 UK 90
11.3.2.1 Investment by pharmaceutical sponsors in the UK for drug discovery services to support market growth 90
11.3.3 FRANCE 92
11.3.3.1 High number of oncology clinical trials in France to drive
market growth 92
11.3.4 ITALY 95
11.3.4.1 High number of clinical trials and the low drug approval time are
the major factors driving market growth 95
11.3.5 SPAIN 97
11.3.5.1 Short study start-up times and rising R&D expenditure to boost
the growth of the Spanish market 97
11.3.6 REST OF EUROPE 99
11.4 ASIA PACIFIC 102
11.4.1 CHINA 105
11.4.1.1 Low cost of clinical trials and large pharmaceutical R&D footprint in China to drive market growth 105
11.4.2 INDIA 108
11.4.2.1 Low-cost services and availability of skilled workforce to support market growth in India 108
11.4.3 JAPAN 110
11.4.3.1 Government initiatives for drug innovation to support market growth in Japan 110
11.4.4 REST OF ASIA PACIFIC 112
11.5 REST OF THE WORLD 114
12 COMPETITIVE LANDSCAPE 118
12.1 OVERVIEW 118
12.2 MARKET SHARE ANALYSIS 118
12.3 COMPETITIVE SCENARIO 119
12.3.1 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 119
12.3.2 SERVICE LAUNCHES 120
12.3.3 MERGERS & ACQUISITIONS 120
12.3.4 EXPANSIONS 121
12.4 COMPETITIVE LEADERSHIP MAPPING 121
12.4.1 VISIONARY LEADERS 121
12.4.2 INNOVATORS 121
12.4.3 DYNAMIC DIFFERENTIATORS 121
12.4.4 EMERGING COMPANIES 121

13 COMPANY PROFILES 123
(Business overview, Services offered, Recent developments, MNM view)*
13.1 LABORATORY CORPORATION OF AMERICA HOLDINGS 123
13.2 EUROFINS SCIENTIFIC SE 125
13.3 CHARLES RIVER LABORATORIES INTERNATIONAL 128
13.4 EVOTEC SE 132
13.5 THERMO FISHER SCIENTIFIC 137
13.6 ALBANY MOLECULAR RESEARCH, INC. 140
13.7 SYNGENE INTERNATIONAL LIMITED 142
13.8 JUBILANT LIFESCIENCES 144
13.9 GENSCRIPT BIOTECH CORPORATION 147
13.10 PIRAMAL ENTERPRISES LIMITED 149
13.11 SELVITA S.A. 151
13.12 AURIGENE DISCOVERY TECHNOLOGIES
(A SUBSIDIARY OF DR. REDDY’S LABORATORIES) 152
13.13 DOMAINEX LTD. 153
13.14 WUXI APPTEC 155
13.15 CHEMPARTNER CO., LTD. 157
13.16 FRONTAGE HOLDINGS 158
13.17 PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC 159
13.18 SHANGHAI MEDICILON, INC. 160
13.19 TCG LIFESCIENCES PVT. LIMITED 160
13.20 VIVA BIOTECH (SHANGHAI) LTD. 161
*Business overview, Services offered, Recent developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 162
14.1 DISCUSSION GUIDE 162
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 165
14.3 AVAILABLE CUSTOMIZATIONS 167
14.4 RELATED REPORTS 168
14.5 AUTHOR DETAILS 169

 

LIST OF TABLES

TABLE 1 DRUG DISCOVERY PROCESS OVERVIEW 37
TABLE 2 RESEARCH PROJECTS FUNDED BY THE IRDIRC 41
TABLE 3 AVERAGE COST OF DRUGS APPROVED PER YEAR, 2004–2013 43
TABLE 4 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018–2025 (USD MILLION) 49
TABLE 5 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2018–2025 (USD MILLION) 50
TABLE 6 ADVANTAGES AND DISADVANTAGES OF SIRNA 50
TABLE 7 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2018–2025 (USD MILLION) 51
TABLE 8 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION,
BY REGION, 2018–2025 (USD MILLION) 52
TABLE 9 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2018–2025 (USD MILLION) 53
TABLE 10 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2018–2025 (USD MILLION) 53
TABLE 11 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 55
TABLE 12 MEDICINAL CHEMISTRY DRUG DISCOVERY SERVICES MARKET, BY REGION,
2018–2025 (USD MILLION) 56
TABLE 13 BIOLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION,
2018–2025 (USD MILLION) 56
TABLE 14 DMPK DRUG DISCOVERY SERVICES MARKET, BY REGION,
2018–2025 (USD MILLION) 57
TABLE 15 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018–2025 (USD MILLION) 59
TABLE 16 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2018–2025 (USD MILLION) 60
TABLE 17 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION,
2018–2025 (USD MILLION) 61
TABLE 18 GLOBAL NUMBER OF CLINICAL TRIALS, BY THERAPEUTIC AREA
(AS OF OCTOBER 2019) 63
TABLE 19 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 64
TABLE 20 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION,
2018–2025 (USD MILLION) 65
TABLE 21 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGY, BY REGION,
2018–2025 (USD MILLION) 66
TABLE 22 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS AND IMMUNE SYSTEM DISEASES, BY REGION, 2018–2025 (USD MILLION) 67
TABLE 23 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES,
BY REGION, 2018–2025 (USD MILLION) 68
TABLE 24 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES,
BY REGION, 2018–2025 (USD MILLION) 69
TABLE 25 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2018–2025 (USD MILLION) 70
TABLE 26 DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE,
2018–2025 (USD MILLION) 72

TABLE 27 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 PHARMACEUTICAL COMPANIES, BY REGION, 2018–2025 (USD MILLION) 72
TABLE 28 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 PHARMACEUTICAL COMPANIES, BY REGION, 2018–2025 (USD MILLION) 73
TABLE 29 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 PHARMACEUTICAL COMPANIES, BY REGION, 2018–2025 (USD MILLION) 73
TABLE 30 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2018–2025 (USD MILLION) 75
TABLE 31 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 77
TABLE 32 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 77
TABLE 33 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 77
TABLE 34 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 78
TABLE 35 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD MILLION) 78
TABLE 36 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2018–2025 (USD MILLION) 78
TABLE 37 NUMBER OF CLINICAL TRIALS STARTED IN THE US, BY COMPANY, 2017 80
TABLE 38 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 80
TABLE 39 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 81
TABLE 40 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 81
TABLE 41 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 81
TABLE 42 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY CONDITION (2019) 82
TABLE 43 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY COMPANY, 2017 83
TABLE 44 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 83
TABLE 45 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 84
TABLE 46 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 84
TABLE 47 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 84
TABLE 48 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 86
TABLE 49 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 86
TABLE 50 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 86
TABLE 51 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 87
TABLE 52 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 87
TABLE 53 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE,
2018–2025 (USD MILLION) 87

TABLE 54 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 88
TABLE 55 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 89
TABLE 56 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 89
TABLE 57 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 89
TABLE 58 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 91
TABLE 59 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 91
TABLE 60 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 91
TABLE 61 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 92
TABLE 62 NUMBER OF CLINICAL TRIALS STARTED IN FRANCE, BY COMPANY, 2017 93
TABLE 63 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 93
TABLE 64 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 94
TABLE 65 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 94
TABLE 66 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 94
TABLE 67 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY, 2017 95
TABLE 68 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 96
TABLE 69 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 96
TABLE 70 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 96
TABLE 71 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 97
TABLE 72 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 98
TABLE 73 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 98
TABLE 74 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 99
TABLE 75 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 99
TABLE 76 ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 100
TABLE 77 ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 101
TABLE 78 ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 101
TABLE 79 ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 101
TABLE 80 TOTAL NUMBER OF CLINICAL TRIALS IN APAC, BY THERAPEUTIC AREA, 2017 102

TABLE 81 APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 103
TABLE 82 APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 104
TABLE 83 APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 104
TABLE 84 APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 104
TABLE 85 APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 105
TABLE 86 APAC: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE,
2018–2025 (USD MILLION) 105
TABLE 87 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 106
TABLE 88 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 107
TABLE 89 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 107
TABLE 90 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 107
TABLE 91 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 108
TABLE 92 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 109
TABLE 93 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 109
TABLE 94 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 109
TABLE 95 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 111
TABLE 96 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 111
TABLE 97 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 111
TABLE 98 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 112
TABLE 99 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 113
TABLE 100 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 113
TABLE 101 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 114
TABLE 102 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 114
TABLE 103 ROW: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION) 115
TABLE 104 ROW: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 116
TABLE 105 ROW: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION) 116
TABLE 106 ROW: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION) 116

TABLE 107 ROW: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE,
2018–2025 (USD MILLION) 117
TABLE 108 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2017–2019) 119
TABLE 109 SERVICE LAUNCHES (2017–2019) 120
TABLE 110 MERGERS & ACQUISITIONS (2017–2019) 120
TABLE 111 EXPANSIONS (2017–2019) 121

 

LIST OF FIGURES

FIGURE 1 DRUG DISCOVERY SERVICES MARKET SEGMENTATION 21
FIGURE 2 RESEARCH DESIGN 23
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 26
FIGURE 4 BOTTOM-UP APPROACH 27
FIGURE 5 TOP-DOWN APPROACH 27
FIGURE 6 DATA TRIANGULATION METHODOLOGY 28
FIGURE 7 DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2020 VS. 2025 (USD MILLION) 30
FIGURE 8 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION) 31
FIGURE 9 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2020 VS. 2025 (USD MILLION) 31
FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2020 VS. 2025 (USD MILLION) 32
FIGURE 11 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2020 VS. 2025 (USD MILLION) 33
FIGURE 12 INCREASING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY TO DRIVE MARKET GROWTH 34
FIGURE 13 SMALL-MOLECULE DRUGS TO ACCOUNT FOR THE LARGEST SHARE OF
THE NORTH AMERICAN DRUG DISCOVERY SERVICES MARKET IN 2020 35
FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH IN THE DRUG DISCOVERY SERVICES MARKET DURING THE FORECAST PERIOD 36
FIGURE 15 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS,
AND OPPORTUNITIES 38
FIGURE 16 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2001–2017 (USD BILLION) 39
FIGURE 17 ACTIVE PHARMACEUTICAL PIPELINE, JANUARY 2009–JANUARY 2019 40
FIGURE 18 NUMBER OF ORPHAN INDICATIONS APPROVED IN THE US (2010–2017) 42
FIGURE 19 NUMBER OF REGISTERED STUDIES (2005–2017) 43
FIGURE 20 AVERAGE COST TO DEVELOP ONE NEW APPROVED DRUG—INCLUDING
THE COST OF FAILURES 44
FIGURE 21 R&D PIPELINE, BY THERAPY GROUP, 2018 & 2019 63
FIGURE 22 TOTAL NUMBER OF CLINICAL TRIALS FOR ONCOLOGY,
BY REGION (AS OF DECEMBER 2019) 65
FIGURE 23 TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA 76
FIGURE 24 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT 76
FIGURE 25 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES,
BY PHASE (JANUARY 2019) 79
FIGURE 26 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013–2017 90
FIGURE 27 SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 2011–2017 97
FIGURE 28 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT 103
FIGURE 29 DRUG DISCOVERY SERVICES MARKET SHARE (2018) 118
FIGURE 30 GLOBAL DRUG DISCOVERY SERVICES MARKET: COMPETITIVE
LEADERSHIP MAPPING (2018) 122

FIGURE 31 LABCORP: COMPANY SNAPSHOT (2018) 123
FIGURE 32 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2018) 125
FIGURE 33 CHARLES RIVER LABORATORIES INTERNATIONAL: COMPANY SNAPSHOT (2018) 128
FIGURE 34 EVOTEC SE: COMPANY SNAPSHOT (2018) 132
FIGURE 35 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018) 137
FIGURE 36 SYNGENE: COMPANY SNAPSHOT (2018) 142
FIGURE 37 JUBILANT LIFESCIENCES: COMPANY SNAPSHOT (2018) 144
FIGURE 38 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2018) 147
FIGURE 39 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2018) 149
"

 

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る